Donor leukocytes in therapeutic blood components are implicated in transfusion-related complications ranging from alloimmuniration t o graft-versus-host disease (GVHD) to viral transmission and reactivation. To further characterize the kinetics of donor leukocyte clearance after allogeneic transfusion, we developed allele-specific polymerase chain reaction ( E R ) assays directed at a single-copy Y chromosome gene and HLA class I 1 alleles. These assays enable sensitive detection and quantiiation of donor leukocytes at concentrations ranging from one cell to greater than 1, OOO cells per 125 FL of recipient blood. When applied to serial samples from five consecutive orthopedic surgery patients who met study criteria, we observed 99.9% clearance of donor leukocytes over the initial 2 days posttransfusion, followed by a transient, l-log increase in circulating donor leukocytes on ELLULAR BLOOD components (whole blood, packed red blood cells [RBC], and platelets) contain 10' to 10" donor leukocytes. Although these leukocytes serve no therapeutic role, they are widely recognized as responsible for a host of transfusion-related complications, ranging from chill-fever reactions to HLA alloimmunization with resulting platelet refractoriness to fatal graft-versus-host disease (GVHD)."" Donor leukocytes also play an important role as vectors for transfusion-transmission of retrovirus and herpes virus infections" and act as allogeneic stimulators for reactivation of recipient viral infection^.'^"^ Several recent studies suggest that donor leukocytes may induce immunologic abnormalities in recipients that lead to increased susceptibility to bacterial infections and recurrence of malignan~ies.l~+'~ Despite the frequency and clinical importance of these leukocyte-induced complications, relatively little is known about the kinetics of survival and clearance of donor leukocytes after transfusions. Early methods for investigation of donor leukocyte survival involved cytogenetic (karyotype) analysis of posttransfusion samples in cases where donors and recipients were of opposite ex.'^"^ Using this technique to study neonatal exchange transfusions, Hutchinson et a1" found that lymphocytes in units from random donors were detectable up to several weeks posttransfusion, whereas lymphocytes could be detected for as long as 2 years after birth after exchange transfusions using maternal blood. Schechter et all' initially reported the transient appearance of activated lymphocytes on days 3 to 7 posttransfusion in immunocompetent recipients of fresh whole blood; in a follow-up study," these investigators used karyotype analysis to show that, although the majority of spontaneously proliferating lymphocytes detected 5 to 10 days posttransfusion were of recipient origin, male donor cells were occasionally also present.
Donor leukocytes in therapeutic blood components are implicated in transfusion-related complications ranging from alloimmuniration t o graft-versus-host disease (GVHD) to viral transmission and reactivation. To further characterize the kinetics of donor leukocyte clearance after allogeneic transfusion, we developed allele-specific polymerase chain reaction ( E R ) assays directed at a single-copy Y chromosome gene and HLA class I 1 alleles. These assays enable sensitive detection and quantiiation of donor leukocytes at concentrations ranging from one cell to greater than 1, OOO cells per 125 FL of recipient blood. When applied to serial samples from five consecutive orthopedic surgery patients who met study criteria, we observed 99.9% clearance of donor leukocytes over the initial 2 days posttransfusion, followed by a transient, l-log increase in circulating donor leukocytes on ELLULAR BLOOD components (whole blood, packed red blood cells [RBC] , and platelets) contain 10' to 10" donor leukocytes. Although these leukocytes serve no therapeutic role, they are widely recognized as responsible for a host of transfusion-related complications, ranging from chill-fever reactions to HLA alloimmunization with resulting platelet refractoriness to fatal graft-versus-host disease (GVHD)."" Donor leukocytes also play an important role as vectors for transfusion-transmission of retrovirus and herpes virus infections" and act as allogeneic stimulators for reactivation of recipient viral infection^.'^"^ Several recent studies suggest that donor leukocytes may induce immunologic abnormalities in recipients that lead to increased susceptibility to bacterial infections and recurrence of malignan~ies.l~+'~ Despite the frequency and clinical importance of these leukocyte-induced complications, relatively little is known about the kinetics of survival and clearance of donor leukocytes after transfusions. Early methods for investigation of donor leukocyte survival involved cytogenetic (karyotype) analysis of posttransfusion samples in cases where donors and recipients were of opposite ex.'^"^ Using this technique to study neonatal exchange transfusions, Hutchinson et a1" found that lymphocytes in units from random donors were detectable up to several weeks posttransfusion, whereas lymphocytes could be detected for as long as 2 years after birth after exchange transfusions using maternal blood. Schechter et all' initially reported the transient appearance of activated lymphocytes on days 3 to 7 posttransfusion in immunocompetent recipients of fresh whole blood; in a follow-up study," these investigators used karyotype analysis to show that, although the majority of spontaneously proliferating lymphocytes detected 5 to 10 days posttransfusion were of recipient origin, male donor cells were occasionally also present.
More recent studies have used molecular techniques such as variable number tandem repeat (VNTR) analysis or DNA fingerprinting to detect mixed chimerisms after bone marrow transplantations or in suspected cases of transfusion-associated GVHD (TA-GVHD).Z0-23 These techniques, which are able to detect minor cell populations when present at frequencies of 1% to lo%, show clearance of donor leukocytes within l to 2 days posttransfusion in the absence of evolving TA-GVHD.20*23 Polymerase chain reaction (PCR)-based approaches for analysis of allelic polymorphisms, which employ primers to conserved regions flanking variable regions followed by hybridization with allele-specific probe^,^.^^ are similarly unable to detect minor populations when present at less than a 1% prevalence. To overcome this problem, primers can be selected that amplify highly repeated genetic sequences unique to the minor population of leukocytes. Using this approach with primers directed at Y chromosome repetitive sequences, Adams et alZ6 recently reported frequent detection of transfused male donor cells up to 7 days posttransfusion. Unfortunately, this study evaluated only single posttransfusion samples for each recipient, and the investigators did not attempt quantitative interpretation of the concentration of donor leukocytes in recipient blood at various time points posttransfusion.
We have applied an alternative PCR-based strategy, termed quantitative sequence-specific PCR (QSS-PCR),27"0 to the question of donor leukocyte clearance. QSS-PCR overcomes earlier limitations by selective amplification (using sequence-or allele-specific primers) of single-copy allelic sequences in nucleated donor cells under conditions that minimize and control for allelic DNA competition in background recipient leukocytes. Quantitation is achieved by parallel analysis of a dilution series of donor blood (or leukocytes) into recipient blood (or leukocytes) obtained before transfusion. When this method was used to study the kinetics of donor leukocyte survival after allogeneic transfusion of immunocompetent subjects, we discovered that, after an initial clearance phase, the concentrations of circulating donor cells increased transiently in recipients.
MATERIALS AND METHODS

Subjects Studied and Transfusion Protocols
Orthopedic surgery patients. Female patients were identified from the University of California, San Francisco (UCSF) Medical Center (San Francisco, CA) Maximum Blood Order Schedule who were scheduled for an elective orthopedic surgery procedure for which at least 1 U of unmanipulated (ie, not irradiated or leukodepleted) packed RBC was likely to be transfused, and from whom autologous blood was not collected. Before selection for the study, the subjects' charts were reviewed to determine indications for surgery and prior pregnancy and transfusion history, and to exclude medical conditions suggesting possible immunodeficiency. Fully screened male donor RBC units less than 14 days old were crossmatched with the selected recipients' blood until a single compatible male donor RBC unit was identified. This unit was designated the index unit. All additional blood components for these patients were selected from the fully screened blood inventory based on their having been collected from female donors. One tubing segment of blood from each donor unit was retained by the transfusion service and forwarded to the testing laboratory for (1) verification of male/ female origin by Y chromosome positivity, (2) HLA-DR typing by allele-specific PCR (see below), and (3) use in dilutional studies (index units) with pretransfusion recipient blood to generate the standard curve for interpretation of donor cell concentrations in posttransfusion samples. Pretransfusion and posttransfusion EDTA-anticoagulated blood samples from the patients were obtained throughout the hospital stay from the hematology laboratory after completion of routinely ordered diagnostic testing. All five patients had uneventful postoperative recoveries without reported transfusion reactions. As no additional procedures (including phlebotomies) were performed for purposes of this study, specific informed consent was not required or obtained from recipients or donors. The study protocol was approved by the UCSF Committee on Human Research.
Canine transfusion studies. Donor blood (1 U) was obtained the day before intended transfusion from a type-compatible, 32-kg male dog by collection into an ACD quad-pack blood bag and processed into three equal packed RBC components with Nutricell additive (Cutter Laboratories, Covena, CA) according to routine blood bank procedure. Three adult female dogs were sedated (acepromizine, 0.05 mg/kg; butorphanol, 0.2 mgkg), and 5 mL venous blood was collected into EDTA tubes as pretransfusion samples. A volume of donor blood estimated to represent l/lo the total blood volume of the recipient was transfused intravenously. Venous blood (3 mL) was collected at 15 minutes, 2 hours, and daily posttransfusion for 1 week. Donor blood for one of the three recipient dogs was exposed to 1,500 cGy gamma irradiation before transfusion, according to standard blood bank procedure.
An additional female dog was transfused on two occasions with fresh ACD-anticoagulated whole blood from a male donor to which the recipient had been previously alloimmunized by repeated transfusions of platelet concentrates, as documented by radiolabeled platelet survival and antibody measurement^.^' A nonimmunized female recipient dog was transfused with platelet-rich plasma from a male donor; the platelet-rich plasma was treated with 8-methoxypsoralin (300 pg/mL) and UV A light (340 to 400 nm; 7.5 k m 2 ) before transfusion. The canine studies were approved by the UCSF and University of Washington (W; Seattle, WA) committees on animal research.
CellDNA Preparation and Processing
To quantitatively recover leukocytes from recipient blood samples, 0.5 mL of anticoagulated whole blood was subjected to RBC lysing using 0.5 mL saponin lysis buffer (0.4% saponin [ICN Biochemicals, Cleveland, OH] in 0.5% NaCI) within 12 to 24 hours of phleb~tomy.~' After a 5-minute incubation at room temperature with intermittent mixing, the tube was centrifuged at 3,000 rpm (600g) for 5 minutes in a microcentrifuge. The leukocyte pellet was then washed twice with 1 mL PCR solution A (100 mmol/L KCl; 10 mmol/L Tris, pH 8.3; 2.5 mmol/L MgCI,), followed by resuspension in 50 pL of PCR solution A and freezing. Leukocyte preparations from serial bleeds from individual recipients were batched, and DNA was prepared by adding 50 pL of PCR lysis solution B (10 mmoU L Tris, pH 8.3; 2.5 mmol/L MgCl,; 1% Tween-20; 1% NP40; 0.4 mg/mL proteinase K) to each pellet and incubating at 60°C for 1.5 hours with vortexing every 20 minutes, followed by 95°C for 2 hours. The DNA lysates from each serial bleed were then tested together in duplicate, both neat and at a 1:lO dilution of each DNA lysate, in a single PCRhybridizatiodpolyacrylamide gel electrophoresis (PAGE)/autoradiography run along with analysis of duplicate standard dilution series. Analysis of a 1:lO dilution of lysates is intended to detect PCR inhibitors, as well as to yield signal in the linear range of the standard curve for samples with high levels of target cells (see below). By testing the serial samples from each patient in a single run, we controlled for possible patient-specific factors (eg, variable background leukocyte concentrations) and eliminated potential between-run variables, such as slight differences in PCR reaction conditions or specific activity.
Development and Standardization of &SS-PCR
Based on published sequence data, we designed primers that would selectively amplify single-copy gene alleles unique to minor target cell populations to be studied (ie, DRI, DR2, and SRY).
For each assay, four candidate primer sequences (see below) were synthesized and evaluated in different combinations. Different amplification reaction mixtures and temperature cycling programs were also evaluated to identify optimal amplification conditions for each primer pair combination. Conditions were first optimized using serial dilutions of DR1-, DR2-, or Y chromosome-positive cells prepared in parallel into buffer and into suspensions of 1 X IO6 DR1-, DR2-, and Y chromosome-negative cells, respectively. For each system, primer combinations and amplification conditions were identified that enabled detection of as few as one to five target leukocytes in a sample containing IO6 allogeneic recipient leukocytes, with accurate quantitation over approximately 3-log concentrations of target cells.
A series of replicate analyses of spiked whole blood samples was then performed to document accuracy and precision of the assay over the quantitative range to be investigated. Three different donor whole blood samples (positive for the target alleles) with known leukocyte concentrations were diluted fourfold, and the serial dilutions were spiked into three different recipient whole blood samples (negative for the target alleles). Each dilution was then processed through the assay system in replicates of five. Means, standard deviations, and coefficients of variation at each spike level were determined.
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PCR Primers and Conditions
HLA DRI ana! DR2 allele-specific PCR. A 91-bp region of DRBl gene was amplified using DRl allele-specific primer pairs designed by us and designated DRlA (5' CTTGTGGCAGCTTAA-GATGCA 3'):' A 258-bp region of DR2 was amplified using allelespecific primers DR2A (5' CTGTGGCAGCCTAAGAGGGAGT 3') and DWG (5' CCGCTGCACTGTGAAGCTCT 3'). The PCR reaction mixture for both DR1 and D W primers consisted of 100 mmoU gelatin, 2 pmoVpL of each primer, 1 mmoVL dNTPs, and 0.12 U/ pL Thermalase (IBI, New Haven, CT). DNA lysate (25 pL; containing cells derived from 125 mL of whole blood) was added to 50 pL of PCR reaction mixture, followed by 35 cycles in an MJR thermocycler (MJ Research, Inc, Watertown, MA). For DR1, each cycle consisted of 25 seconds at 9 5 T , 1 minute at 56"C, and 1.5 minutes at 72°C. For DR2, each cycle consisted of 25 seconds at 9 5 T , followed by 2 minutes at 72°C. Y chromosome sequence-specific PCR. A 148-bp region of the sex-determining region of the human Y chromosome (SRY)34,35 was amplified using allele-specific primer pair SA (5' CGCAl'TCAT-GAATGGCC 3'). The PCR reaction mixture consisted of 100 rnmoll gelatin, 1 pmol/pL of each primer, and 0.04 U/pL Thermalase. DNA lysate (25 pL) was added to 50 pL of PCR reaction mixture, followed by amplification for 30 cycles consisting of 30 seconds at 9 5 T , 2 minutes at 70°C. For canine studies, a 100-bp region of the SRY was amplified using primer pair SA (5' CGCA'ITCATCGTGTG-GTCTCGCG 3') and SC (5' CCACTGGTATCCCAGCTGCTTGC 3')"' The PCR reaction mixture consisted of 100 mmoVL KCI, 20 mmol/L Tris HCI pH 8.3, 2.5 mmom MgCI2, 0.02% gelatin, 2 pmoUpL of each primer, and 0.04 WpL Thermalase. DNA lysate (25 pL) was added to 50 pL of PCR reaction mixture, followed by amplification for 30 cycles consisting of 30 seconds at 9 5 T , 2 minutes at 70°C. 
Probe Sequences and Hybridization Conditions
Specific amplified products were detected by oligomer liquid hybridization using 32P-labeled probes: DRlB (5' GGTGCGGlTGCTGGAAAG 3') for HLA DRl gene, DR2B (5' TTCCTG-GACAGATACTTC 3') for HLA DR2 gene, and SB (5' GAG-GCGCAAGATGGCTCTAGAG 3') for human and canine Y chromosome^.^^^^^ The probes were end-labeled at 37°C for 1 hour in a 40-pL solution consisting of 7 mmol/L Tris HCL pH 7.6, 10 mmoVL MgClz, 15 mmoVL dithiothreitol, 10 U T4 polynucleotide Kinase (New England Biologicals, Cambridge, MA), 40 pCi "Padenosine triphosphate ("P-ATP; Dupont, Wilmington, DE) and 30 pmol probes. After incubation, the volume was adjusted to 400 pL by addition of 0.75 mmoVL NaCl and 10 mmoVL EDTA solution. For hybridization, 10 pL of this probe mix was added to 30 pL of postamplification specimen and incubated for 5 minutes at 59°C after a 5-minute denaturation at 95°C.
Detection and Quantitation
To each hybridized sample, 10 pL of loading buffer (0.25% bromphenol blue, 0.25% xylene cyanol, and 30% glycerol) was added, and this mixture was subjected to 6% PAGE at 12.5 V/cm. After running, the gel was exposed to XAR-5 autoradiographic film (Kod a k , Rochester, NY) with enhancing screen for 2 hours and overnight at room temperature. Duplicate standard curves composed of 10-fold serial dilutions of donor in pretransfusion recipient cells (lo', lo2, 10, 1) were analyzed in parallel with clinical samples and used to interpolate donor leukocyte concentration in test samples. Autoradiographs were analyzed using the Millipore BioImage Electrophoresis Analyzer (Millipore, Ann Arbor, MI) with Whole Band Analyzer application software (Millipore). Image analysis was performed on the dilution (neat or 1: 10) and film exposure (2 hours or overnight) that was within the linear range of the corresponding standard curve on that film. Values from duplicate determinations were averaged. If both dilutions (neat and 1:lO) were within the dynamic range, both were analyzed, and the results were averaged (after adjusting for the dilution factor). The autoradiograph image was first acquired by the computer using a transmissive scanner (Howtek Scanmaster 3+; Howtek, Hudson, NH). After manual input of gel margins, numbers of lanes per gel, and numbers of gels per image, the program finds the bands corresponding to amplified DNA and places lane indicators. The program then draws boundaries around the bands and measures the intensity of each band width, subtracting background intensity of that lane. Internal concentration standards are assigned to the bands resulting from the standard curve amplifications. The program then compares unknown samples against the standard curve samples using linear interpolation to determine the concentration of the unknown through a formula taking into account the area and intensity of each band. The reproducibility of the image analysis system was assessed by replicate (5X) scanning of 23 sample data points spanning the assay's dynamic range (two to 500 cells): the mean percent coefficient of variation (CV) was 8.32%, with a range of 3.7% to 17.8%.
RESULTS
Reproducibility of Assay Systems
After optimization of each assay system (see Materials and Methods), we performed replicate whole blood dilution studies to document accuracy and precision over a range of target cell concentrations. For example, for the SRY system, three different male donor whole blood samples with known leukocyte concentrations were diluted fourfold, and serial dilutions corresponding to two to 500 white blood cells ( W C ) were spiked into three different female recipient whole blood samples. Each dilution was then processed through the assay protocol in replicates of five. The results, summarized in Table l, indicate that the assay has a CV of approximately 50% over this dynamic range and can, therefore, accurately discriminate fourfold differences in target cell concentrations. Similar results were obtained with assays for HLA-Drl and -Dr2 alleles (data not shown) and for an HLA-DQ-A-specific PCR assay designed for quantitation of residual leukocytes in filtered blood units.32
For
Donor Leukocyte Survival Studies in Humans
Our first donor leukocyte survival study involved tracing leukocytes in 1 U of packed RBC from a male, DR1-positive donor after transfusion (3 days postcollection) into a &-yearold, DR1-negative woman undergoing total hip replacement. The number of infused donor leukocytes was calculated based on weight of the blood bag pretransfusion and posttransfusion and the leukocyte concentration of the residual blood in the bag after transfusion. Using the recipient's estimated blood volume, we calculated a theoretical concentration of donor cells immediately posttransfusion (assuming a bolus infusion and complete equilibration with no immediate clearance). Blood specimens collected at serial time points posttransfusion were then evaluated using QSS-PCR directed at Y chromosome and DRl target genes to determine posttransfusion donor leukocyte survival, expressed as the concentration of donor cells per milliliter of recipient peripheral blood.
As seen in Fig 1, a progressive decline in circulating donor leukocytes was observed over the first 3 days posttransfusion, with a nadir of approximately 10 donor cells per milliliter of blood on day 3 in patient 1. This was followed by an approximately 10-fold increase in the concentration of circulating donor leukocytes at 4 days posttransfusion, followed by a secondary clearance of donor cells on days 5 to 7.
In this patient, an additional RBC unit from a DR1-positive, female donor was infused on the afternoon of day 5. Note that PCR signal attributable to transfused leukocytes in this unit was detected on day 6 using the DR1 system (Fig 1B) but, because the donor was female, not the Y chromosome system (Fig IA) . Figure 2 shows QSS-PCR results using the Y chromosome system for four additional female orthopedic surgery patients, each transfused with single units of male donor M C . These patients ranged in age from 17 to 47 years, and received index RBC units that had been stored at 4°C for from 4 to 14 days before transfusion. Although the posttransfusion sampling time points for several of these patients were not as complete as for the patient shown in Fig 1, all except patient 5 showed results consistent with a decline in circulating male donor leukocytes over the first 2 to 3 days posttransfusion, followed by an increase in the concentration of donor cells on days 3 through 5.
Donor Leukocyte Survival in Canine Transfusion Model
The kinetics of donor leukocyte clearance after transfusion were further studied in the canine transfusion model.31 In initial studies, two female recipients were transfused with 80 mL of l-day-old RBC components derived from a single male donor dog; a third female dog was transfused with 70 mL of gamma-irradiated (1,500 cGy) RBC from the same male donor dog. Samples collected immediately posttransfusion and then daily for 7 days were tested by QSS-PCR analysis directed at canine Y chromosome-specific sequences. For the recipients of nonirradiated blood, the kinetics of initial clearance, followed by a transient increase in circulating male donor leukocytes, were similar to that was observed in humans (Fig 3A) . In contrast, in the recipient of irradiated RBC, the transient increase in circulating donor leukocytes at days 3 to 5 posttransfusion was not observed (Fig 3B) .
An additional female dog, which had been previously alloimmunized to a male donor as determined by platelet antibody studies and rapid clearance of radiolabeled platelets:' was transfused on two occasions with fresh, nonirradiated whole blood from the donor dog. T h i s alloimmunized dog showed accelerated donor leukocyte clearance (ie, no male cells detectable by 24 hours posttransfusion) and no evidence of subsequent increase in circulating donor leukocytes. Finally, a nonalloimmunized female recipient was transfused on two occasions with platelet-rich plasma that was treated with 8-methoxypsoralin and UV-A light before transfusion. The results for both transfusions were similar to those after transfusion of irradiated blood, with initial leukocyte clearance by day 3 and no detectable subsequent increase in circulating donor cells (data not shown).
DISCUSSION
Although previous investigators have reported detection of donor leukocytes in the circulation of immunocompetent recipients during the first week posttransf~sion,'~~'~~~~~~~ the kinetics of clearance have not been previously characterized. In the present study, we used a QSS-PCR assay directed at donor Y chromosome and HLA sequences to quantitatively study donor leukocyte survival after allogeneic transfusion. In both humans and dogs, we observed a progressive decline in circulating donor leukocytes over the first several days posttransfusion, followed by an approximately 10-fold increase in the concentration of donor leukocytes 3 to 6 days posttransfusion. The increase in circulating donor leukocytes was not detected in female dogs transfused with gammairradiated or photosensitized (8-methoxypsoralin and UV-A) blood, which suggests that this leukocyte expansion phase may be due to proliferation of donor leukocytes (probably lymphocytes), rather than recirculation of cells that were sequestered in the spleen or reticuloendothelial system. Thus, as first hypothesized by Schechter et all8 in 1972 and later r e v i e~e d :~~~~ transfusion of blood containing viable donor leukocytes may routinely lead to a two-way proliferative reaction, consisting of an attempted graft-versus-host reaction by donor cells and allograft rejection by recipient cells. The timing of the initial increase in circulating donor leukocytes observed in our studies (days 3 to 5) is consistent with the 8-to 12-day delay between transfusion and clinical presentation of TA-GVHD,s assuming that a lag-time of 3 to 7 days exists between earliest detection of increasing donor leukocytes by our assay and development of the levels of effector T cells necessary to induce clinical GVHD. In immunocompetent recipients such as those we studied, the donor leukocyte expansion phase is presumably aborted by an effective recipient immune response against the donor cells." In contrast, in immunosuppressed recipients or in homozygous recipients of haplotype-mismatched transfusions, donor leukocyte expansion may progress unchecked, leading to clinical GVHD.38 Further studies will be required to establish that the transient donor leukocyte expansion phase observed in our study represents an allotypic proliferaFor personal use only. on April 14, 2017 . by guest www.bloodjournal.org From In addition to a possible relationship to GVHD, the transient donor leukocyte expansion phase observed in our study may have relevance to several other complications of blood transfusions. The absence of detection of a donor leukocyte recirculation phase in a dog that was alloimmunized to its donor suggests a possible relationship between the donor leukocyte expansion phenomenon and alloimmunization. The fact that gamma-irradiated blood can induce a plateletrefractory state4" clearly indicates that mitotic expansion of donor cells is not a prerequisite to alloimmunization. However, there may be a continuum in alloimmunogenic potential, ranging from fresh, viable leukocytes to intact but nonviable leukocytes to leukocyte membrane fragments:' Future studies should investigate the relationship between the kinetics of donor leukocyte clearance and recipient immune activation posttransfusion, with development of alloimmunization, as well as the effect of manipulations intended to reduce alloimmunization (eg. leukodepletion and photochemical t r e a t r n e n t~~~~) on these phenomena.
Lang45 first proposed a relationship between mitotic proliferation of donor and recipient leukocytes after transfusion and induction of latent viral infections in donor and recipient leukocytes. Subsequent animal14 and humanMA7 studies have indicated that viable, allogeneic donor leukocytes are instrumental in inducing both primary and reactivation cytomegalovirus (CMV) infections after transfusions. Recent in vitro4* and clinical s t u d i e~~~.~' suggest that transfusion of donor leukocytes may reactivate human immunodeficiency virus (HIV) and may lead to increased opportunistic infections (particularly CMV) and accelerated mortality in HIV-infected patients. A multicenter study of transfusion-induced viral reactivation and GVHD in HIV-infected patients will begin clinical activity in early 1995 (E. Sloand, National Heart, Lung and Blood Institute). In this study, leukocyte survival kinetics will be monitored using quantitative PCR techniques similar to those used in the present study, and the results will be correlated with viral reactivation and clinical outcome. In conclusion. our results indicate that the concentration of donor leukocytes in recipient blood increases transiently 3 t o S clays posttransfusion. We hypothesize that this transient increase in circulating donor leukocytes represents one a r m o f a n in vivo mixed lymphocyte reaction. with activated donor T lymphocytes proliferating i n an abortive GVHD reaction to HLA-incompatible recipient cells. Further investigation of this phenomenon should provide insight into the mechanisms involved in donor-recipient leukocyte interactions posttransfusion and the relationship of these interactions to leukocyte-induced complications.
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